Clinical

A French real-world study of 282 patients with CLL identified 2 distinct treatment profiles shaped by age, genetics, and logistics—not trial data alone.

Explore 5 FAQs on CDC opioid guidelines, including dosing, tapering, monitoring, and managed care strategies to reduce overdose risk.

Off-the-shelf cema-cel clears MRD at more than triple the rate of observation alone—and may propel a shift to frontline use of CAR T-cell therapy when relapse is hard to detect.

Nicole A. Caffiero, PharmD, MBA, BCACP, concluded AMCP 2026 by highlighting key themes shaping the specialty drug market.

A faster, cheaper alternative to karyotyping, DNA index testing shows near-perfect accuracy for detecting high hyperdiploidy in pediatric patients with leukemia.

FDA approves doravirine/islatravir, a once-daily, 2-drug, single-tablet HIV regimen showing noninferior efficacy to standard therapies in suppressed adults.

PFAS exposure, especially PFDA, was linked to higher nonmelanoma skin cancer odds, with stronger effects observed in older adults.

Young-onset CRC mortality rose over 3 decades in the US, largely among adults with lower educational attainment, widening socioeconomic gaps.

Benjamin Lockshin, MD, FAAD, offers a forward-looking synthesis of how psoriasis care has evolved toward holistic, personalized management—and where advances in oral therapies, biomarker-guided selection, and equitable access will define the next era of treatment.

Real-world data suggest long-acting injectables may help achieve—not just maintain—viral suppression.

Radium-223 retains a role in osteoblastic bone-only disease, while PSMA PET has become indispensable across staging, recurrence detection, and patient selection for radioligand therapy.

Clinicians should consider systemic immunotherapy earlier in CSCC—especially in moderate- to high-risk cases—using a multidisciplinary, patient-centered approach to guide treatment decisions.

TETON-1 data show inhaled treprostinil improves FVC and reduces worsening in IPF, supporting a potential new treatment and combo strategy.

A new study finds that highly lethal cancers receive less research support than lower-risk cancers.

Experts from AMCP discuss the real-world evidence on GLP-1 usage and health care spending.

A new review explains how new therapies and technologies are guiding the treatment of acute myeloid leukemia (AML).

New myeloma therapies—CAR T, bispecific antibodies, and oral CELMoDs—expand options, protect QOL, and raise hopes of cure, notes Asya Nina Varshavsky-Yanovsky, MD, PhD.

Experts at AMCP 2026 urged smarter oncology management amid rising costs, complex therapies, and fragmented oversight across plans.

The FDA is encouraging drug sponsors to pursue a new indication for testosterone replacement therapy.

During an afternoon AMCP 2026 session, experts called for integrated clinical and payer care models to combat rising metabolic disease prevalence, costs, and complexity.

The authors updated a diagnosis list to identify low-acuity emergency department visits by veterans and applied it to examine trends and predictors of veterans’ low-acuity utilization.

Steven Kheloussi, PharmD, explains how care coordination and transparent policies can improve MS treatment adherence, streamline access, and balance costs.

A new meta-analysis finds patients who have CLL with “borderline” IGHV status have intermediate outcomes, supporting the need for more precise risk classification.

Patients who were treatment naive or had switched to rituximab saw short-term results of reduced disease activity in multiple sclerosis.

A recent study identified persistent myocardial fibroblast activation in patients with heart failure with reduced ejection fraction, with distinct patterns by etiology.